Press Releases

Date Title and Summary Additional Formats
Toggle Summary Patent Broadly Protects Cytotoxic T Cells Expressing a Chimeric Antigen Receptor that are Derived from Pluripotent Stem Cells SAN DIEGO , Aug. 14, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed Read All » View HTML
Toggle Summary No FT500 DLTs Reported at Second Cell Dose Level in Monotherapy Arm or at First Cell Dose Level in Checkpoint Inhibitor Combination Arm in Solid Tumor Study Successfully Completed FT516 GMP Production and Product Release for Initiation of First-ever Clinical Trial of Engineered iPSC-derived Cell Read All » View HTML
Toggle Summary SAN DIEGO , July 30, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live Read All » View HTML
Toggle Summary SAN DIEGO , July 17, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Dr. Read All » View HTML
Toggle Summary SAN DIEGO , May 30, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko , President and Chief Executive Read All » View HTML
Toggle Summary First-ever Patient Treated in U.S. with an iPSC-derived Cell Therapy Successfully Advances through Six-dose Treatment Course No Dose-Limiting Toxicities or Serious Adverse Events Reported in Initial Cohort of FT500 iPSC-derived NK Cell Cancer Immunotherapy Patients FT500 Clinical Trial Now Open for Read All » View HTML
Toggle Summary SAN DIEGO , April 30, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and Read All » View HTML
Toggle Summary SAN DIEGO , April 24, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Fate scientists and collaborators will present Read All » View HTML
Toggle Summary SAN DIEGO , April 18, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Yu-Waye (Wayne) Chu , M.D. Read All » View HTML
Toggle Summary No Dose-Limiting Toxicities or Serious Adverse Events Reported following Three Once Weekly Doses of Universal, Off-the-Shelf NK Cell Product Candidate New Preclinical Data of Universal, Off-the-shelf, iPSC-derived NK Cell Product Candidates FT516 and FT596 Highlighted at 2019 AACR Annual Meeting Read All » View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.